24. Longitudinal Assessment of Immune Responses to COVID-19 Vaccines in Solid Organ Transplant Recipients
Oral Abstracts
[키워드] 95% CI
anti-N IgG
anti-RBD
anti-S
anti-S IgG
Anti-S1
antibody
assessment
baseline
black
BNT162b2
board
cellular response
Characteristics
Clinical efficacy
Cohort
collected
consultant
controls
coronavirus disease
COVAX
COVID
COVID-19
COVID-19 vaccine
Cutoff
DAVID
demographics
detect
domain
dose
Efficacy
enrolled
evaluate
figure
first dose
greater
healthy
healthy control
humoral
IgG antibodies
IgG titer
longitudinal
magnitude
median
member
mRNA COVID-19 vaccine
mRNA vaccine
mRNA-1273
natural infection
participant
Pfizer
Phase 3 trials
plasma
positive
positive response
prospective cohort study
Quanterix Corporation
RBD
receive
recipient
recipients
reducing
Research
respond
response
Result
risk
SARS-CoV-2
second dose
serological response
significantly
significantly lower
Simoa
Solid
solid organ transplant
SOT
spike
sub-cohort
subset
T-cell Response
table
the healthy
the SARS-CoV-2
threshold
time
timepoint
timepoints
titer
Transplant
understanding
Vaccine
vaccine response
were excluded
were used
with COVID-19
[DOI] 10.1093/ofid/ofab466.024 PMC 바로가기 [Article Type] Oral Abstracts
[DOI] 10.1093/ofid/ofab466.024 PMC 바로가기 [Article Type] Oral Abstracts